---
title: Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic
  cancer cultures
date: '2024-06-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38941955/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240629181533&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a tumour entity
  with unmet medical need. To assess the therapeutic potential of oncolytic virotherapy
  (OVT) against PDAC, different oncolytic viruses (OVs) are currently investigated
  in clinical trials. However, systematic comparisons of these different OVs in terms
  of efficacy against PDAC and biomarkers predicting therapeutic response are ...'
disable_comments: true
---
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a tumour entity with unmet medical need. To assess the therapeutic potential of oncolytic virotherapy (OVT) against PDAC, different oncolytic viruses (OVs) are currently investigated in clinical trials. However, systematic comparisons of these different OVs in terms of efficacy against PDAC and biomarkers predicting therapeutic response are ...